Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus–Related Hospitalization in Newborns
Compared with maternal vaccination with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.
Authors
- A. Gabet (ORCID: https://orcid.org/0000-0003-1273-8988)
- Marion Bertrand (ORCID: https://orcid.org/0000-0002-4115-7093)
- Valérie Olié (ORCID: https://orcid.org/0000-0002-4837-1930)
- Epiphane Kolla (ORCID: https://orcid.org/0000-0003-4649-6833)
- M. Zureik
- Marie-Joelle Jabagi
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
Publication Details
- Journal
- JAMA
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1001/jama.2025.24082
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71